Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peroxisomal disorders.

G V Raymond1

  • 1Kennedy Krieger Institute, Baltimore, Maryland 21205, USA. raymond@kennedykrieger.org

Current Opinion in Pediatrics
|December 11, 1999
PubMed
Summary
This summary is machine-generated.

Peroxisomal disorders stem from genetic defects in PEX genes, impacting peroxisome assembly. Current therapies show limited success, with ongoing research into treatments like docosahexaenoic acid and phenylbutyrate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo loss of function mutations in KIAA2022 are associated with epilepsy and neurodevelopmental delay in females.

Clinical genetics·2016
Same author

Childhood Cerebral Adrenoleukodystrophy: MR Perfusion Measurements and Their Use in Predicting Clinical Outcome after Hematopoietic Stem Cell Transplantation.

AJNR. American journal of neuroradiology·2016
Same author

Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

AJNR. American journal of neuroradiology·2015
Same author

Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines.

Molecular genetics and metabolism·2015
Same author

Onset of adreno-leukodystrophy after medulloblastoma therapy: causal connection or coincidence?

JIMD reports·2013
Same author

Contrast enhancement of brainstem tracts in Zellweger spectrum disorder: evidence of inflammatory demyelination?

Neuropediatrics·2011
Same journal

For health, for beauty, or both? navigating trends as adolescent clinicians.

Current opinion in pediatrics·2026
Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026
Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026
Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026
Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026
Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026
See all related articles

Area of Science:

  • Cell Biology
  • Genetics
  • Biochemistry

Background:

  • Peroxisomes are vital organelles in eukaryotic cells, performing diverse biochemical functions.
  • Genetic defects in peroxisome biogenesis and enzyme abnormalities lead to severe diseases.
  • Peroxisome assembly disorders, such as Zellweger syndrome, result from mutations in PEX genes.

Purpose of the Study:

  • To review the genetic basis of peroxisomal disorders.
  • To discuss current therapeutic approaches and their limitations.
  • To highlight emerging treatments for peroxisomal diseases.

Main Methods:

  • Literature review of genetic defects in peroxisome biogenesis.
  • Analysis of current therapeutic strategies for peroxisomal disorders.

Related Experiment Videos

  • Evaluation of novel therapeutic agents like docosahexaenoic acid, phenylbutyrate, and lovastatin.

    • Main Results:

    • Genetic defects in PEX genes disrupt peroxisome assembly and function.
    • Existing therapies for peroxisomal disorders have shown limited clinical efficacy.
    • Investigational therapies show promise but require further clinical validation.

    Conclusions:

    • Understanding the genetic underpinnings of peroxisomal disorders is crucial for developing effective treatments.
    • Novel therapeutic avenues are being explored, offering hope for patients.
    • Further research is essential to determine the clinical benefit of emerging therapies.